info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Tardive Dyskinesia Treatment Market Research Report: By Treatment Type (Antipsychotic Medications, Cholinergic Agents, GABAergic Agents, Glutamatergic Agents, Botulinum Toxin Injections), By Disease Severity (Mild, Moderate, Severe), By Treatment Setting (Inpatient, Outpatient, Home Healthcare), By End-User (Patients, Caregivers, Hospitals, Clinics, Pharmacies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032


ID: MRFR/HC/26006-HCR | 100 Pages | Author: Rahul Gotadki| October 2024

Global Tardive Dyskinesia Treatment Market Overview


As per MRFR analysis, the Tardive Dyskinesia Treatment Market Size was estimated at 3.55 (USD Billion) in 2022.

The Tardive Dyskinesia Treatment Market Industry is expected to grow from 3.82(USD Billion) in 2023 to 7.52 (USD Billion) by 2032. The Tardive Dyskinesia Treatment Market CAGR (growth rate) is expected to be around 7.81% during the forecast period (2024 - 2032).


Key Tardive Dyskinesia Treatment Market Trends Highlighted


The Tardive Dyskinesia Treatment Market is characterized by the rising prevalence of tardive dyskinesia, primarily induced by the prolonged use of antipsychotics. The increasing awareness of the condition and the unmet medical needs drive the demand for effective treatments.Technological advancements have led to the development of novel therapies, including gene editing techniques and neuromodulation devices, offering new avenues for symptom management. The market is further influenced by government initiatives and research collaborations aimed at improving patient outcomes.Recent trends indicate a shift towards personalized medicine, with tailored treatments based on individual patient profiles and genetic factors. Additionally, there is a growing emphasis on early diagnosis and intervention, recognizing the importance of prompt treatment to prevent irreversible damage.


Tardive Dyskinesia Treatment Market Overview


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Tardive Dyskinesia Treatment Market Drivers


Rising Prevalence of Tardive Dyskinesia


Tardive dyskinesia (TD) is a movement disorder that can develop in individuals who take certain medications for an extended period of time, particularly antipsychotics. The prevalence of TD is increasing globally due to several factors, including the aging population, increased use of antipsychotics and better recognition of the condition. The growing number of TD cases is driving the demand for effective treatment options, contributing to the growth of the Tardive Dyskinesia Treatment Market Industry.


Advancements in Treatment Approaches


The Tardive Dyskinesia Treatment Market Industry is witnessing substantial progression in the treatment of the disease. The researchers are focusing on discovering new pharmacological and non-pharmacological interventions to treat TD. Several therapies, such as deep brain stimulation, transcranial magnetic stimulation, and gene therapy, have been discovered, and many new are in the pipeline which is expected to increase the treatment options for patients and the market growth.


Growing Awareness and Patient Advocacy


Increased awareness about TD among healthcare professionals and patients is contributing to the growth of the Tardive Dyskinesia Treatment Market Industry. Patient advocacy groups are playing a crucial role in educating the public about TD, promoting early diagnosis, and advocating for improved access to treatment. The growing awareness and patient advocacy efforts are creating a more favorable environment for the development and commercialization of effective TD treatments.


Tardive Dyskinesia Treatment Market Segment Insights


Tardive Dyskinesia Treatment Market Treatment Type Insights


The Tardive Dyskinesia Treatment Market is segmented by Treatment Type as Antipsychotic Medications, Cholinergic Agents, GABAergic Agents, Glutamatergic Agents, and Botulinum Toxin Injections. Antipsychotic Medications dominated the Tardive Dyskinesia Treatment Market, with more than 50% market share. This can be primarily attributed to the fact that Antipsychotic Medications are the first line of treatment. The Cholinergic Agents are expected to grow significantly during the forecast period because they are more potent than the existing medications in improving motor symptoms.GABAergic Agents and Glutamatergic Agents are also getting attention in the ongoing research to establish their role in subduing the symptoms of Tardive Dyskinesia. This is mainly attributed to the increasing prevalence of the disorder, rising awareness about the condition, and evolving treatment modalities. The market is also expected to be catalyzed by the growing geriatric population because Tardive Dyskinesia is primarily witnessed among them. Future developments can also revolve around the advent of safe and potent medications with minimal side effects and the use of stem cells to modulate the condition.


Tardive Dyskinesia Treatment Market Treatment Type Insights


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Tardive Dyskinesia Treatment Market Disease Severity Insights


The Tardive Dyskinesia Treatment Market is segmented by disease severity into mild, moderate, and severe. Among these, the moderate segment is expected to hold the largest market share of around 42.7% by 2023. This is because moderate TD is the most common type, affecting an estimated 50% of the patients with TD. The mild segment is expected to be growing at the CAGR of 8.5% during the forecast period, as the timely detection and treatment of TD can enhance the treatment outcome. The severe segment is expected to occupy a market share of around 27.3% by 2023, as it requires intensive care and is highly prone to complications.


Tardive Dyskinesia Treatment Market Treatment Setting Insights


Outpatient settings are expected to dominate the Tardive Dyskinesia Treatment Market, accounting for a revenue share of over 55% in 2024. The growing preference for outpatient care due to its convenience, lower costs, and advancements in medication administration techniques are driving this segment's growth. Home healthcare is also expected to witness significant growth, primarily driven by the increasing geriatric population and the rising demand for home-based care services. Inpatient settings, while having a smaller market share, play a crucial role in managing severe cases of tardive dyskinesia and providing intensive care and support.


Tardive Dyskinesia Treatment Market End-User Insights


The Tardive Dyskinesia Treatment Market can be segmented based on end-users, with the major segments being patients, caregivers, hospitals, clinics and pharmacies. The largest segment in terms of revenue is hospitals, which accounted for over 50% of the global market in 2023. This is due to the fact that hospitals are the primary setting for the diagnosis and treatment of tardive dyskinesia. Clinics are the second largest segment, followed by pharmacies. The patient segment is expected to grow at the highest CAGR over the forecast period, as the increasing prevalence of tardive dyskinesia is leading to a greater demand for treatment.


Tardive Dyskinesia Treatment Market Regional Insights


The regional segmentation of the Tardive Dyskinesia Treatment Market offers valuable insights into the distribution of market share and growth opportunities across key regions. North America is projected to maintain its dominance, capturing a significant share of the market revenue in 2023. This dominance is primarily driven by factors such as the high prevalence of mental health disorders, established healthcare infrastructure, and ongoing research and development activities in the region. Europe follows closely behind, with a substantial market share and increasing adoption of novel therapies.The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by rising healthcare expenditure, growing awareness of tardive dyskinesia, and increasing access to medical facilities. South America and the Middle East and Africa (MEA) regions are also anticipated to contribute to the overall market growth, albeit at a slower pace.


Tardive Dyskinesia Treatment Market Regional Insights


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Tardive Dyskinesia Treatment Market Key Players And Competitive Insights


The Tardive Dyskinesia Treatment Market is a dynamic and competitive landscape with a diverse range of players. Key industry leaders include AbbVie, Allergan, Neurocrine Biosciences, Teva Pharmaceutical Industries, and Sunovion Pharmaceuticals. These companies hold a significant market share and drive innovation in the development and commercialization of Tardive Dyskinesia treatments. The Tardive Dyskinesia Treatment Market has witnessed strategic partnerships, mergers and acquisitions, and collaborations among players to expand their portfolios and gain a competitive edge.Leading Tardive Dyskinesia Treatment Market PlayersAbbVieAbbVie is a global biopharmaceutical company headquartered in the United States. The company has a strong presence in the Tardive Dyskinesia Treatment Market with its blockbuster drug, Depakote (valproic acid). Depakote is a widely prescribed medication for the treatment of seizures and bipolar disorder and has also been shown to reduce symptoms of Tardive Dyskinesia. AbbVie's focus on research and development has led to the expansion of its Tardive Dyskinesia Treatment portfolio with the development of newer and more effective therapies.Competitor companyAllerganAllergan is an American pharmaceutical company specializing in ophthalmology, dermatology, medical aesthetics, and neurology. The company's involvement in the Tardive Dyskinesia Treatment Market stems from its expertise in neurology. Allergan's key Tardive Dyskinesia Treatment product is Botox (onabotulinumtoxinA), a neuromodulator used for treating a range of neurological disorders. Allergan has been actively engaged in clinical trials and research to evaluate the efficacy and safety of Botox in managing Tardive Dyskinesia symptoms. The company's commitment to innovation and patient care positions it as a formidable competitor in the Tardive Dyskinesia Treatment Market.


Key Companies in the Tardive Dyskinesia Treatment Market Include



  • Teva

  • Amneal

  • Sun Pharmaceutical Industries

  • Apotex

  • Mylan

  • Reddy's Laboratories

  • Actavis

  • Cadila Healthcare

  • Glenmark Pharmaceuticals

  • Torrent Pharmaceuticals

  • Abbott

  • Lupin

  • Sandoz

  • Cipla


Tardive Dyskinesia Treatment Market Industry Developments


The Tardive Dyskinesia Treatment Market is expected to grow significantly over the forecast period, driven by the rising prevalence of tardive dyskinesia and the increasing demand for effective treatments. In 2023, the market was valued at USD 3.82 billion and is projected to reach USD 7.52 billion by 2032, exhibiting a CAGR of 7.81%. Key factors contributing to market growth include the growing geriatric population, the increasing use of antipsychotic medications, and the rising awareness of tardive dyskinesia. Moreover, the development of novel therapies and the expansion of treatment options are anticipated to further propel market growth.


Tardive Dyskinesia Treatment Market Segmentation Insights


Tardive Dyskinesia Treatment Market Treatment Type Outlook



  • Antipsychotic Medications

  • Cholinergic Agents

  • GABAergic Agents

  • Glutamatergic Agents

  • Botulinum Toxin Injections


Tardive Dyskinesia Treatment Market Disease Severity Outlook



  • Mild

  • Moderate

  • Severe


Tardive Dyskinesia Treatment Market Treatment Setting Outlook



  • Inpatient

  • Outpatient

  • Home Healthcare


Tardive Dyskinesia Treatment Market End-User Outlook



  • Patients

  • Caregivers

  • Hospitals

  • Clinics

  • Pharmacies


Tardive Dyskinesia Treatment Market Regional Outlook



  • North America

  • Europe

  • South America

  • Asia Pacific

  • Middle East and Africa

Report Attribute/Metric Details
Market Size 2022 3.55(USD Billion)
Market Size 2023 3.82(USD Billion)
Market Size 2032 7.52(USD Billion)
Compound Annual Growth Rate (CAGR) 7.81% (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
Market Forecast Units USD Billion
Key Companies Profiled Teva, Amneal, Sun Pharmaceutical Industries, Apotex, Mylan, Dr. Reddy's Laboratories, Actavis, Cadila Healthcare, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Abbott, Lupin, Sandoz, Cipla
Segments Covered Treatment Type, Disease Severity, Treatment Setting, End-User, Regional
Key Market Opportunities Rising prevalence of tardive dyskinesia Growing geriatric population. Technological advancements in drug development Increasing research and development activities Emerging markets with untapped potential.
Key Market Dynamics Aging Population Rising Prevalence Therapeutic Advancements Increasing Healthcare Expenditure Growing Demand for Early Diagnosis
Countries Covered North America, Europe, APAC, South America, MEA


Frequently Asked Questions (FAQ) :

The Tardive Dyskinesia Treatment Market is expected to reach USD 7.52 billion by 2032, growing at a CAGR of 7.81% from 2024 to 2032.

The increasing prevalence of tardive dyskinesia, rising awareness of treatment options, and the introduction of novel therapies are the key factors driving the growth of the market.

North America is expected to hold the largest market share due to the high prevalence of tardive dyskinesia, well-established healthcare infrastructure, and the presence of key market players in the region.

The oral segment is expected to account for the largest revenue share due to the convenience of oral administration and the availability of a wide range of oral medications for tardive dyskinesia.

Key competitors in the market include Teva Pharmaceutical Industries Ltd., Allergan, Inc., Lundbeck A/S, Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline plc.

The limited efficacy of current treatments, the development of side effects associated with long-term use of medications, and the lack of awareness about tardive dyskinesia in developing countries are the major challenges faced by the market.

The development of more effective and safer therapies, the increasing use of personalized medicine approaches, and the growing focus on early diagnosis and intervention are the key trends expected to shape the future of the market.

The Tardive Dyskinesia Treatment Market is expected to grow at a CAGR of 7.81% from 2023 to 2032.

The forecast period for the Tardive Dyskinesia Treatment Market is from 2023 to 2032.

The base year for the Tardive Dyskinesia Treatment Market is 2023.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.